Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
174 hedge funds and large institutions have $2.46B invested in Sage Therapeutics in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 74 increasing their positions, 52 reducing their positions, and 37 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 52
2.25% more ownership
Funds ownership: 102.94% → 105.18% (+2.2%)
8% less funds holding
Funds holding: 190 → 174 (-16)
20% less capital invested
Capital invested by funds: $3.06B → $2.46B (-$599M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
35% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 37
39% less call options, than puts
Call options by funds: $66.5M | Put options by funds: $109M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$88.6M |
| 2 |
Bank of New York Mellon
New York
|
+$56.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$15.5M |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$14.5M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$13.3M |
Top Sellers
| 1 |
MWNA
Marshall Wace North America
New York
|
-$22.4M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$22.1M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$19.3M |
| 4 |
Jennison Associates
New York
|
-$16.9M |
| 5 |
Barclays
London,
United Kingdom
|
-$11.7M |
SAGE Hedge Fund Activity: Q3 2017 in Review
174 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2017, worth a combined $2.46B — down 20% from $3.06B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of SAGE and 24 opened new positions — a net loss of 13 holders — while 52 trimmed existing stakes and 74 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $88.6M. The largest seller was Marshall Wace North America, cutting an estimated $22.4M.
- 174 institutional investors held Sage Therapeutics (SAGE) as of Q3 2017, down from 190 in Q2 2017.
- Funds reported $2.46B of Sage Therapeutics stock for Q3 2017, down 20% quarter-over-quarter.
- 24 funds opened new Sage Therapeutics positions in Q3 2017 and 37 closed out, a net change of -13 holders.
- The largest Sage Therapeutics buyer in Q3 2017 was T. Rowe Price Associates, an estimated $88.6M added.
- The largest Sage Therapeutics seller in Q3 2017 was Marshall Wace North America, an estimated $22.4M sold.
Based on aggregated 13F filings for Q3 2017.